Description

Bensedin 10 mg (Diazepam) Tablets

Bensedin 10 mg is a high-strength pharmaceutical oral formulation manufactured with diazepam as its active pharmaceutical ingredient (API). Classified as a long-acting classical benzodiazepine, diazepam acts as a positive allosteric modulator at central nervous system $\text{GABA}_A$ receptor complexes. By increasing the frequency of chloride channel opening in response to gamma-aminobutyric acid ($\text{GABA}$), it amplifies neuronal hyperpolarization, delivering broad anxiolytic, anticonvulsant, central muscle relaxant, and sedative effects.

Product Overview

Primary Indications

Bensedin 10 mg is prescribed under qualified clinical supervision for:

• Severe Anxiety & Tension States: Rapid control and short-term symptomatic relief of severe, disabling anxiety disorders, acute agitation, and stress-related psychoneurotic states.

• Acute Alcohol Withdrawal Syndrome: Treatment of acute neuro-excitation, tremor, motor agitation, impending delirium tremens, and acute hallucinosis.

• Musculoskeletal Spasms & Spasticity: Adjunctive management of skeletal muscle spasms caused by local trauma, inflammation, or neurological disorders affecting upper motor neurons (e.g., spastic diplegia, cerebral palsy, spinal lesions).

• Convulsive Disorders: Maintenance and adjunctive oral therapy for refractory seizure disorders, helping stabilize seizure frequency alongside baseline antiepileptic drugs.

• Preoperative Sedation: Pre-procedural tranquilization and sedation to mitigate perioperative stress and anxiety.

Key Information & Precautions

• Dosage & Titration: 10 mg is the highest standard single-tablet strength of diazepam. Therapy is commonly initiated at lower doses (2 mg to 5 mg) and titrated upward only when medically justified to prevent excessive central depression.

• Cumulative Toxicity & Elderly Risk: Due to extensive lipophilicity and long-acting active metabolites, diazepam accumulates with repeated dosing. Geriatric patients and individuals with hepatic insufficiency clear the drug substantially slower, markedly raising the risk of cumulative over-sedation, motor ataxia, confusion, and fall-related fractures.

• Physical Dependence & Tolerance: Prolonged administration beyond 2 to 4 weeks significantly elevates the risk of physical dependence, psychological tolerance, and substance misuse. Therapy should always be restricted to the minimum effective dose for the shortest viable duration.

• Severe Withdrawal Hazard: Abrupt cessation following chronic therapy can provoke life-threatening withdrawal crises, including status epilepticus, severe autonomic instability, delirium, hallucinations, and intense rebound anxiety. Discontinuation mandates a gradual, medically supervised step-down tapering protocol.

• Boxed Warning — Concomitant Depressants: Co-administration with opioids, alcohol, or other sedative-hypnotics carries a critical risk of synergistic CNS depression, respiratory arrest, coma, and fatal overdose.

• Psychomotor & Cognitive Impairment: Patients must avoid driving, operating heavy machinery, or engaging in safety-critical tasks until individual sedation and reaction times are clinically assessed.